Skip to content

o2h Ventures launches new SEIS/EIS fund

o2h Ventures, an investment firm which specialises in backing biotech companies, has launched a new SEIS/EIS fund.

o2h Ventures offers private investors the opportunity to back promising medical innovations via an Enterprise Investment Scheme (EIS) and Seed Investment Scheme (SEIS). The o2h Therapeutics Fund is an early stage SEIS/EIS fund investing in biotech therapeutic and related AI opportunities.

Sunil Shah, CEO of o2h Ventures, said: “We are really excited to launch the o2h Ventures Therapeutics Fund. We see great deal flow through our network which is an accumulation of more than 15 years of providing research services to this sector.

“Pharmaceutical companies are now interested in purchasing biotech companies at an earlier stage. Although this usually means they pay a lower price, it still represents a very attractive return for early investors.

“The EIS benefits are a great way to invest in these fledgling businesses as they develop and become of interest to potential buyers, and a great way to access great British innovation in therapeutics whilst mitigating the risk through the tax benefits. Such investments also provide opportunities for investors to diversify their portfolios.”

The Fund, which is about to make its first investment, will support a number of the companies in the o2h SciTech Park community which was acquired by o2h Ventures.

Shah added: “Early stage companies often need more than just money; o2h Ventures has built a unique integrated model for early stage companies which includes the possibility of offering companies incubation in its o2h SciTech Park in Cambridge, but also with the option to jump-start their research activity from o2h Discovery in Ahmedabad, India.”

o2h Ventures says that large pharmaceutical companies have been closing down research centres globally for the last decade. This shift in focus by the large pharmaceutical companies has moved them from developing innovation in-house to acquiring innovation externally, forcing up the prices for the best science and providing earlier exit opportunities.

The areas of disease that interest o2h Ventures include: alzheimer’s, anti-aging, antibiotics, auto-immune, cancer, inflammation, and Macular Degenerative Disease (wAMD).